Suburethral Slings for Incontinence: Effective Solution or Health Concern?

Urinary incontinence affects millions of women worldwide. Among the treatment options available, suburethral slings have become one of the most common surgical approaches since the 2010s, with tens of thousands implanted each year. However, growing reports of post-operative complications have sparked debate about their safety.

What are suburethral slings?

Suburethral slings are small mesh implants - about 10 cm long and 1 cm wide - typically made of polypropylene. They are positioned under the urethra to provide mechanical support, especially during physical effort like coughing, sneezing, or exercising. The goal is to reduce or eliminate episodes of stress incontinence.

That said, slings aren’t the only treatment available. In some cases, pelvic floor therapy or lifestyle changes may be sufficient. If surgery is recommended, a detailed assessment is essential, including urodynamic testing, to evaluate pressure levels in the urinary tract and tailor the intervention to the individual patient.

Complications and clinical concerns

Several adverse effects have been documented - ranging from minor issues to more serious complications:

• Short-term risks: bladder injury, bleeding, or surgical trauma to the lower urinary tract,
• Intermediate complications (1-6 weeks post-op): hematomas, groin pain, urinary tract infections (reported in 22-32% of cases),
• Long-term issues: sling erosion, infection of the implant, voiding difficulties, chronic pain, or sexual dysfunction.

In approximately 6% of cases, a second procedure is required to partially or fully remove the sling. Health authorities such as the French National Agency for Medicines (ANSM) have issued alerts encouraging healthcare professionals to use these devices with caution.

Ongoing controversies and regulation changes

Medical debate and international scrutiny

Since 2014, regulatory bodies across the globe have examined the use of suburethral slings. In the United States, the FDA reclassified them as high-risk devices (Class III). The UK and Australia have imposed tighter controls or temporarily removed them from clinical use, citing a need for more research and safety data. The European Union created working groups to assess risks and monitor outcomes.

Manufacturers and professionals reevaluate their approach

Some companies, such as ETHICON and BARD, have voluntarily withdrawn their mesh products from the market. Many surgeons are also shifting toward alternative solutions, including non-surgical therapies or less invasive techniques. The rising number of reported side effects, legal actions, and patient complaints has led to mounting distrust in the device’s long-term safety.

While suburethral slings have offered relief to many women struggling with incontinence, they must be used with careful consideration. A full diagnostic workup and open discussion between patient and physician are crucial before making a treatment decision.